Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05281731 | RECRUITING | Glioblastoma

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
Sponsor:

Washington University School of Medicine

Brief Summary:

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

Condition or disease

Glioblastoma

Glioblastoma Multiforme

Intervention/treatment

Sonobiopsy

Research blood

Cancer Personalized Profiling

Definity®

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 40 participants
Masking : NONE
Primary Purpose : DIAGNOSTIC
Official Title : Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
Actual Study Start Date : 2022-04-18
Estimated Primary Completion Date : 2028-11-30
Estimated Study Completion Date : 2028-11-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. Scan must have occurred no more than 28 days prior to enrollment.
  • * Lesion must be \> 3 cm in maximal dimension on MRI.
  • * Lesion must be in the supratentorial space within 5 cm of the cortical surface.
  • * Lesion must be gadolinium enhancing.
  • * Low grade tumors and metastatic tumors
  • * Recurrent brain tumors and/or radiation necrosis
  • * Must be planning to undergo surgical resection of the tumor.
  • * Must be at least 18 years old.
  • * Patients with recurrent GBM who are planning to undergo surgical resection or laser ablation of the recurrent tumor. Recurrence must be confirmed on MRI performed no more than 28 days prior to enrollment.
Exclusion Criteria
  • * Contraindication to MRI.
  • * Previous cranial surgery.
  • * Previous history of cancer and/or cancer treatments.
  • * Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normal parameters and platelets \< 100,000/mcL.
  • * Physical skull defect of any kind.
  • * Ferrous material in the scalp or skull.
  • * Scalp or skin disease that limits contact with the ultrasound probe.
  • * Enrolled in another clinical trial where intervention is administered prior to surgery.
  • * Known hypersensitivity to polyethylene glycol.
  • * Known unstable cardiopulmonary condition (e.g. acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias).
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Location Details

NCT05281731

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Missouri

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110